Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Bought by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC grew its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 3.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 932,231 shares of the company's stock after buying an additional 32,041 shares during the quarter. ArrowMark Colorado Holdings LLC owned 0.92% of Dyne Therapeutics worth $21,963,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. KBC Group NV increased its position in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after purchasing an additional 978 shares in the last quarter. Summit Investment Advisors Inc. boosted its position in shares of Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after acquiring an additional 721 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Dyne Therapeutics during the fourth quarter worth approximately $257,000. Magnetar Financial LLC purchased a new stake in shares of Dyne Therapeutics during the 4th quarter valued at $263,000. Finally, E Fund Management Co. Ltd. increased its position in shares of Dyne Therapeutics by 11.8% in the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock worth $279,000 after acquiring an additional 1,249 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DYN. Chardan Capital restated a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 17th. Scotiabank started coverage on shares of Dyne Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective for the company. Piper Sandler dropped their target price on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. JPMorgan Chase & Co. reduced their target price on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Finally, Guggenheim reiterated a "buy" rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $47.46.

Dyne Therapeutics Stock Up 19.4 %

Shares of Dyne Therapeutics stock traded up $1.82 during trading on Thursday, hitting $11.22. 3,891,990 shares of the stock traded hands, compared to its average volume of 2,395,667. The firm's fifty day moving average is $10.40 and its 200-day moving average is $18.47. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $47.45. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -3.15 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 6,237 shares of company stock valued at $77,760 over the last three months. Corporate insiders own 20.77% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.